PapersFlow Research Brief
Clostridium difficile and Clostridium perfringens research
Research Guide
What is Clostridium difficile and Clostridium perfringens research?
Clostridium difficile and Clostridium perfringens research is a field studying the epidemiology, treatment, and prevention of Clostridium difficile infection, alongside related Clostridium perfringens aspects, with emphasis on fecal microbiota transplantation, antibiotic-associated diarrhea, healthcare-associated infections, toxin production, and clinical practice guidelines.
This research area encompasses 73,142 works on Clostridium difficile infection, focusing on microbiome diversity, vancomycin and metronidazole treatment, risk factors, and bacterial toxins. Studies highlight the role of gut microbiota in antibiotic-associated diarrhea and healthcare-associated infections. Key investigations address toxin production mechanisms and prevention strategies through fecal microbiota transplantation.
Topic Hierarchy
Research Sub-Topics
Clostridium difficile Toxin Production
This sub-topic examines the molecular mechanisms of toxin A and B production by Clostridium difficile, including regulation of toxin gene expression and structural biology of toxins. Researchers study toxin-mediated pathogenesis and develop inhibitors targeting toxin activity.
Fecal Microbiota Transplantation for C. difficile
This sub-topic investigates the efficacy, safety, and mechanisms of fecal microbiota transplantation (FMT) as a treatment for recurrent Clostridium difficile infection. Researchers analyze donor selection, microbiota engraftment, and long-term outcomes.
Antibiotic-Associated Diarrhea Epidemiology
This sub-topic covers the population-level incidence, risk factors, and transmission dynamics of antibiotic-associated diarrhea caused by Clostridium difficile. Researchers use surveillance data to model healthcare-associated outbreaks.
Vancomycin and Metronidazole Treatment Resistance
This sub-topic explores the clinical efficacy, resistance patterns, and pharmacokinetic optimization of vancomycin and metronidazole for Clostridium difficile infection. Researchers compare treatment outcomes and investigate fidaxomicin alternatives.
Clostridium perfringens Enterotoxin Pathogenesis
This sub-topic focuses on the role of Clostridium perfringens enterotoxin (CPE) in foodborne gastroenteritis, including toxin receptor interactions and intestinal damage mechanisms. Researchers study vaccine development and strain virulence.
Why It Matters
Clostridium difficile research directly impacts clinical management of healthcare-associated infections, where antibiotic-associated diarrhea affects patients post-vancomycin or metronidazole treatment. Fecal microbiota transplantation serves as a targeted prevention method, restoring microbiome diversity disrupted by bacterial toxins. Clinical practice guidelines from this field guide risk factor assessment in hospitals, reducing recurrence rates of Clostridium difficile infection as detailed in epidemiological studies within the 73,142 works.
Reading Guide
Where to Start
"Enterotypes of the human gut microbiome" by Arumugam et al. (2011), as it provides foundational understanding of gut microbiome structures relevant to Clostridium difficile infection and microbiome diversity disruptions.
Key Papers Explained
"Enterotypes of the human gut microbiome" (Arumugam et al., 2011) defines stable gut community types, which Lozupone et al. (2012) in "Diversity, stability and resilience of the human gut microbiota" extends to microbiota resilience against perturbations like antibiotics causing Clostridium difficile. Bäckhed et al. (2005) in "Host-Bacterial Mutualism in the Human Intestine" connects this to host-microbe balance disrupted in infections, while Smith et al. (2013) in "The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis" and Furusawa et al. (2013) in "Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells" link metabolites to immune regulation protecting against pathogens.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers emphasize clinical practice guidelines for vancomycin, metronidazole, and fecal microbiota transplantation integration, with focus on epidemiology of healthcare-associated infections and risk factors in ongoing studies.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Enterotypes of the human gut microbiome | 2011 | Nature | 7.4K | ✓ |
| 2 | Diversity, stability and resilience of the human gut microbiota | 2012 | Nature | 5.3K | ✓ |
| 3 | Host-Bacterial Mutualism in the Human Intestine | 2005 | Science | 5.2K | ✓ |
| 4 | The Microbial Metabolites, Short-Chain Fatty Acids, Regulate C... | 2013 | Science | 5.0K | ✓ |
| 5 | Commensal microbe-derived butyrate induces the differentiation... | 2013 | Nature | 5.0K | ✕ |
| 6 | Role of the Microbiota in Immunity and Inflammation | 2014 | Cell | 5.0K | ✓ |
| 7 | The gut microbiota shapes intestinal immune responses during h... | 2009 | Nature reviews. Immuno... | 4.9K | ✓ |
| 8 | Host-Gut Microbiota Metabolic Interactions | 2012 | Science | 4.6K | ✕ |
| 9 | Induction of Intestinal Th17 Cells by Segmented Filamentous Ba... | 2009 | Cell | 4.4K | ✓ |
| 10 | The Impact of the Gut Microbiota on Human Health: An Integrati... | 2012 | Cell | 3.7K | ✓ |
Frequently Asked Questions
What is the role of fecal microbiota transplantation in Clostridium difficile research?
Fecal microbiota transplantation restores microbiome diversity disrupted by Clostridium difficile infection. It addresses antibiotic-associated diarrhea by repopulating beneficial gut bacteria. This approach is emphasized in studies on treatment and prevention within the field.
How does microbiome diversity relate to Clostridium difficile infection?
Microbiome diversity protects against Clostridium difficile by maintaining a balanced gut ecosystem. Reduced diversity from antibiotics increases risk of infection and toxin production. Research shows this link in 73,142 works on antibiotic-associated diarrhea.
What treatments are studied for Clostridium difficile?
Vancomycin and metronidazole treatments target Clostridium difficile infection. These antibiotics address healthcare-associated infections but can disrupt microbiome diversity. Clinical practice guidelines evaluate their efficacy against bacterial toxins.
What are key risk factors for Clostridium difficile infection?
Antibiotic use leading to antibiotic-associated diarrhea is a primary risk factor. Healthcare settings amplify transmission of bacterial toxins. Epidemiology studies in this field identify these factors across 73,142 papers.
What is toxin production in Clostridium difficile research?
Toxin production by Clostridium difficile causes severe diarrhea and tissue damage. Research examines toxin mechanisms in infection pathology. Prevention strategies target these toxins via microbiome restoration.
How does Clostridium perfringens fit into this research?
Clostridium perfringens research overlaps with Clostridium difficile in toxin production and gut infection studies. Both involve antibiotic-associated risks and epidemiology. The field covers their roles in infectious diarrhea.
Open Research Questions
- ? How can fecal microbiota transplantation be optimized to prevent recurrence of Clostridium difficile infection?
- ? What specific microbiome compositions confer resilience against Clostridium difficile toxin production?
- ? Which risk factors most strongly predict healthcare-associated Clostridium difficile outbreaks?
- ? How do vancomycin and metronidazole alter long-term microbiome diversity in treated patients?
- ? What mechanisms link antibiotic-associated diarrhea to Clostridium perfringens and difficile co-infections?
Recent Trends
The field maintains 73,142 works with sustained focus on fecal microbiota transplantation and microbiome diversity, as no growth rate data indicates stability.
Keyword trends highlight vancomycin and metronidazole treatment alongside toxin production studies.
No recent preprints or news alter epidemiology or prevention emphases from the core 73,142 papers.
Research Clostridium difficile and Clostridium perfringens research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Clostridium difficile and Clostridium perfringens research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers